Impact Factor
7.883
Call For Paper
Volume 10 Issue 12 December 2024
LICENSE
EFFECT OF COVISHIELD
-
Author(s):
Sandip D Pagare | Andhale A.K | Kamble H.V.
-
Keywords:
Covishield, Vaccine Effectiveness, Test-negative Design
-
Abstract:
Covishield (ChAdOx1-nCOV Or AZD1222) Is A Recombinant, Replication-deficient Chimpanzee Adenovirus Vector Encoding The SARS-CoV-2 S Glycoprotein Vaccine Currently Being Developed By The Serum Institute Of India (SII), Pune, Based On The AstraZeneca-Oxford
Other Details
-
Paper id:
IJSARTV8I1156971
-
Published in:
Volume: 8 Issue: 11 November 2022
-
Publication Date:
2022-11-23
Download Article